Test2
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient, you
must not copy this message or attachment or disclose the contents to any other
person. If you have received this transmission in erro
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient, you
must not copy this message or attachment or disclose the contents to any other
person. If you have received this transmission in error, pl
t the careers pages on
https://career012.successfactors.eu/career?company=merckgroup and enter the
Requisition ID: 151627.
With best regards,
Pascal Girard
Director, Head of Pharmacometry
Merck
Merck Institute for Pharmacometrics,
EPFL Innovation Park - Building I, CH-1015 Lausanne, Switzerland
el, Switzerland
Phone: +41 61 324 4676
phil.l...@novartis.com<mailto:phil.l...@novartis.com>
From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com>
[mailto:owner-nmus...@globomaxnm.com] On Behalf Of Pascal Girard
Sent: 06 April 2016 10:39
To: Naoto Hayashi; jgre...@btco
Dear Naoto,
In the past, Rene Bruno got one poster accepted with discussion at ASCO. He is
our ”champion” !
I got one accepted on model for Exp-Tumor Size – OS at European Cancer Congress
2013 . But I can tell you that a medical writer rewrote it entirely and it took
1 month to get it reviewed
Dear All,
Thanks all for your replies. I will not reply to each. Just to say that of
course I know that forest plots come from Meta Analysis, which by the way may
be already familiar to clinicians.
It has been advocated by FDA to report DDI see (Menon-Andersen D, Yu B,
Madabushi R, Bhattaram
from
the CRAN.
Has anyone developed such a package?
With best regards / Mit freundlichen Grüßen / Cordialement / 祝好 / よろしくお願いします
Pascal
Pascal Girard
Director, Pharmacometry
Merck Serono | Global Early Development
"Merck – Living Innovation"
Merck Institute for Pharm
cal aspects of M&S in drug development
* Is enthusiastic, self-motivated and has good communication
skills, and at ease in working in a dynamic matrix organization; is a
team-player. Communicate technical details effectively with scientists and
clinicians colleagues
With best reg
r. Communicate technical details effectively with scientists and
clinicians colleagues
To apply please visit the careers pages on
https://career012.successfactors.eu/career?company=merckgroup and enter the
following Requisition ID 41221 for the manager position in Darmstadt.
With best regard
Dear Aziz,
NM does not return the asymptotic SE of THETA(1) in model 1 on the log-scale.
So I would use model 2.
With best regards / Mit freundlichen Grüßen / Cordialement
Pascal
From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com] On
Behalf Of Chaouch Aziz
Sent: 11 Febru
nd enter the
following Requisition ID 41221 for the manager position in Darmstadt or
Requisition ID 59283 for the Senior Scientist in Lausanne or Darmstadt.
With best regards,
Pascal Girard
Director, Pharmacometry
Merck Serono | Global Early Development
"Merck - Living Innovat
Test
Pascal Girard
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient, you
must not copy this message or attachment or disclose the contents to any other
person. If you have received this
layer.
Communicate technical details effectively with scientists and clinicians
colleagues
To apply please visit the careers pages on
https://career012.successfactors.eu/career?company=merckgroup and enter the
following Requisition ID 41221.
With best regards,
Pascal Girard
Director,
Dear Anuhbia,
Since bootstrap is performed to replace the estimation of precision that
is performed in the $COV step, you definitively do not need the $COV
option when you do a bootstrap.
Then CI are obtained based on the quantiles of the bootstrap estimates.
Kind regards,
Pascal Girard
the one with the dummy
points.
> > 4) I decided to redo the grid with only one dummy point every 1/4 of
> > time unit. The result was less dramatic, but still for most of my
> > individuals the EBEs predictions were diverging from the original
ones
> > computed without
=1 to your original dataset you sometimes get very
> different EBEs ? Are there cases/models/ADVAN where the problem is
> likely to happen? Is their a way to fix it it in NONMEM other than the
> trick I used?
>
> Thanks for your replies!
>
> Kind regards,
>
> Pasca
sometimes get very
different EBEs ? Are there cases/models/ADVAN where the problem is likely
to happen? Is their a way to fix it it in NONMEM other than the trick I
used?
Thanks for your replies!
Kind regards,
Pascal Girard, PhD
pascal.gir...@merckgroup.com
Head of Modeling & Simula
ways got the "Fatal Error: Record SIZES is not valid" message.
I looked into Help guide viii (pp 166-167 and 463-464) but did not find
any relevant information how to set $SIZES. What would be your suggestion?
Thanks again for your help, because it's highly frustrating not being
;s highly frustrating not being able
to use the multi-cores when you have such long runs.
Kind regards
Pascal Girard, PhD
pascal.gir...@merckgroup.com
Head of Modeling & Simulation - Oncology
Global Exploratory Medicine
Merck Serono S.A. · Geneva
Tel: +41.22.414.3549
Cell: +
Thanks again for your help, because it's highly frustrating not being able
to use the multi-cores when you have such long runs.
Kind regards
Pascal Girard, PhD
pascal.gir...@merckgroup.com
Head of Modeling & Simulation - Oncology
Global Exploratory Medicine
Merck Serono S.
not find
any relevant information how to set $SIZES. What would be your suggestion?
Thanks again for your help, because it's highly frustrating not being able
to use the multi-cores when you have such long runs.
Kind regards
Pascal Girard, PhD
pascal.gir...@merckgroup.com
Head of Modeling &
bove?
Thank you for your help,
Kind regards
Pascal Girard, PhD
pascal.gir...@merckgroup.com
Head of Modeling & Simulation - Oncology
Global Exploratory Medicine
Merck Serono S.A. · Geneva
Tel: +41.22.414.3549
Cell: +41.79.508.7898
This message and any attachment are confidential and may be
, Liu J, Qiu R, Frame B, Miller R. Exposure-response
analysis for spontaneously reported dizziness in pregabalin-treated
patient with generalized anxiety disorder. Clin Pharmacol Ther. 2008
Jul;84(1):127-35.
Kind regards / Mit freundlichen Grüßen / Bien cordialement
Pascal Girard, PhD
pascal.gir
share some of this experience. Thank you in
advance for your replies.
Kind regards,
Pascal Girard
This message and any attachment are confidential and may be privileged or
otherwise protected from disclosure. If you are not the intended recipient, you
must not copy this message or attachment or
nd software (MONOLIX, Bayesian software, TS2,
optimal pop PK/PD designs ?) would be an asset, together with knowledge of
R/Splus, SAS or Matlab programming languages.
Interested candidates should send their application to Martin Baltes,
Human Resources - Merck KGaA - Darmstadt (martin.bal...@merck.de).
25 matches
Mail list logo